脱毛症の市場規模、シェア、動向分析レポート：疾患タイプ別、治療法別、性別、販売チャネル別、最終用途別、地域別、セグメント予測、2025年～2030年

脱毛症市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、脱毛症の世界市場規模は2025年から2030年にかけてCAGR 8.7%を記録し、2030年には160億2,000万米ドルに達すると予測されています。

JAK阻害剤とチロシンキナーゼ阻害剤の承認と対象疾患の有病率の上昇が市場成長の原動力になると予想されます。

円形脱毛症（AA）および距骨脱毛症の有病率は世界的に増加しています。2023年3月に発表された調査論文によると、米国と英国では、皮膚科クリニックで新たに遭遇する症例の0.6％～2％が円形脱毛症です。世界中で行われた病院ベースの調査では、AAの発生率は0.57％から3.8％と推定されています。

新しい標的治療薬の承認は、脱毛症市場の成長を促進する重要な要因です。例えば、2022年6月、米国FDAは、成人患者の重症脱毛症の治療薬としてリリーのオルミエント経口錠剤を承認し、承認された最初の全身治療薬となりました。2023年に承認されると予想されるもう一つの重要な薬剤は、ファイザーのリトレシチニブです。これはヤヌスキナーゼ3（JAK3）とチロシンキナーゼの二重阻害剤です。

業界の成長を促進するもう一つの重要な要因は、脱毛症に対する意識の高まりと、それによる世界の治療率の上昇です。外見に対する意識レベルの向上は、治療を求める人々が増加している主な理由の一つです。さらに、研究開発や資金調達への投資が増加していることも、市場の成長を後押ししています。

基礎疾患を治療する標的治療薬の入手可能性が限られていることは、同市場にとって重要な課題の1つです。標的作用機序を持つ新製品が承認されつつある一方で、既に承認された製品に比べこれらの薬剤のコストが高いことが、普及を妨げる大きな要因の1つとなっています。

脱毛症市場レポートハイライト

• 登録前段階にあるPfizer社のRitlecitinibや、第2相臨床試験段階にあるBioniz Therapeutics社のBNZ-1などのパイプライン製品の承認が目前に迫っていることから、2025年から2030年にかけては、円形脱毛症分野が最も急速な成長を遂げると予測されます。
• 2024年の市場は北米が支配的であったが、これは主に消費者意識の高さ、技術の進歩、対象疾患人口の多さ、ヘルスケア支出の多さによるものです。
• アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想されます。その主な理由は、対象疾患人口の増加と治療率の上昇です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 脱毛症市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 脱毛症市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 特許満了分析
• パイプライン分析
  • フェーズ1
  • フェーズ2
  • フェーズ3

第4章 脱毛症市場：疾患タイプの推定・動向分析

• 疾患タイプ別市場シェア、2024年および2030年
• セグメントダッシュボード
• 疾患タイプ別世界の脱毛症市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 円形脱毛症
  • 瘢痕性脱毛症
  • 牽引性脱毛症
  • 全頭脱毛症
  • 汎発性脱毛症
  • 男性型脱毛症
  • その他

第5章 脱毛症市場：治療推定・動向分析

• 治療法別市場シェア、2024年および2030年
• セグメントダッシュボード
• 治療法別世界の脱毛症市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 医薬品
  • デバイス

第6章 脱毛症市場：性別推定・動向分析

• 性別市場シェア、2024年と2030年
• セグメントダッシュボード
• 性別世界の脱毛症市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 男性
  • 女性

第7章 脱毛症市場：販売チャネルの推定・動向分析

• 販売チャネル別市場シェア、2024年および2030年
• セグメントダッシュボード
• 販売チャネル別世界の脱毛症市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 処方箋
  • 市販薬

第8章 脱毛症市場：最終用途の推定・動向分析

• 最終用途別市場シェア、2024年および2030年
• セグメントダッシュボード
• 最終用途別世界の脱毛症市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 在宅ケア設定
  • 皮膚科クリニック

第9章 脱毛症市場：地域の推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018年から2030年まで：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company market share analysis, 2024
  • Janssen Global Services Inc.
  • Cipla
  • Merck &Co., Inc.
  • GSK plc
  • Sun Pharmaceuticals Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Aurobindo Pharma
  • Viatris Inc.
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Lexington Intl., LLC（Devices）
  • Freedom Laser Therapy（iRestore ID-520 helmet）
  • Curallux, LLC.
  • Apira Science Inc.（iGROW Laser）
  • Revian Inc.
  • Theradome
  • Lutronic

List of Tables

• Table 1 List of abbreviation
• Table 2 North America alopecia market, by region, 2018 - 2030 (USD Million)
• Table 3 North America alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 4 North America alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 5 North America alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 6 North America alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 7 North America alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 8 U.S. alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 9 U.S. alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 10 U.S. alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 11 U.S. alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 12 U.S. alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 13 Canada alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 14 Canada alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 15 Canada alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 16 Canada alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 17 Canada alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 18 Mexico alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 19 Mexico alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 20 Mexico alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 21 Mexico alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 22 Mexico alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 23 Europe alopecia market, by region, 2018 - 2030 (USD Million)
• Table 24 Europe alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 25 Europe alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 26 Europe alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 27 Europe alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 28 Europe alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 29 Germany alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 30 Germany alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 31 Germany alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 32 Germany alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 33 Germany alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 34 UK alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 35 UK alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 36 UK alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 37 UK alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 38 UK alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 39 France alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 40 France alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 41 France alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 42 France alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 43 France alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 44 Italy alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 45 Italy alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 46 Italy alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 47 Italy alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 48 Italy alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 49 Spain alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 50 Spain alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 51 Spain alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 52 Spain alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 53 Spain alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 54 Denmark alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 55 Denmark alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 56 Denmark alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 57 Denmark alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 58 Denmark alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 59 Sweden alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 60 Sweden alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 61 Sweden alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 62 Sweden alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 63 Sweden alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 64 Norway alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 65 Norway alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 66 Norway alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 67 Norway alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 68 Norway alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific alopecia market, by region, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 74 Asia Pacific alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 75 China alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 76 China alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 77 China alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 78 China alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 79 China alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 80 Japan alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 81 Japan alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 82 Japan alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 83 Japan alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 84 Japan alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 85 India alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 86 India alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 87 India alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 88 India alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 89 India alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 90 South Korea alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 91 South Korea alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 92 South Korea alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 93 South Korea alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 94 South Korea alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 95 Australia alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 96 Australia alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 97 Australia alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 98 Australia alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 99 Australia alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 100 Thailand alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 101 Thailand alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 102 Thailand alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 103 Thailand alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 104 Thailand alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 105 Latin America alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 106 Latin America alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 107 Latin America alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 108 Latin America alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 109 Latin America alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 110 Brazil alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 111 Brazil alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 112 Brazil alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 113 Brazil alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 114 Brazil alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 115 Argentina alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 116 Argentina alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 117 Argentina alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 118 Argentina alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 119 Argentina alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 120 MEA alopecia market, by region, 2018 - 2030 (USD Million)
• Table 121 MEA alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 122 MEA alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 123 MEA alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 124 MEA alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 125 MEA alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 126 South Africa alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 127 South Africa alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 128 South Africa alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 129 South Africa alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 130 South Africa alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 131 Saudi Arabia alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 136 UAE alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 137 UAE alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 138 UAE alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 139 UAE alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 140 UAE alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 141 Kuwait alopecia market, by disease type, 2018 - 2030 (USD Million)
• Table 142 Kuwait alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 143 Kuwait alopecia market, by gender, 2018 - 2030 (USD Million)
• Table 144 Kuwait alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 145 Kuwait alopecia market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Alopecia market: market outlook
• Fig. 14 Alopecia competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Alopecia market driver impact
• Fig. 20 Alopecia market restraint impact
• Fig. 21 Alopecia market strategic initiatives analysis
• Fig. 22 Alopecia market: Disease type movement analysis
• Fig. 23 Alopecia market: Disease type outlook and key takeaways
• Fig. 24 Alopecia areata market estimates and forecast, 2018 - 2030
• Fig. 25 Male alopecia areata market estimates and forecast, 2018 - 2030
• Fig. 26 Female alopecia areata market estimates and forecast, 2018 - 2030
• Fig. 27 Cicatricial alopecia market estimates and forecast, 2018 - 2030
• Fig. 28 Male cicatricial alopecia market estimates and forecast, 2018 - 2030
• Fig. 29 Female cicatricial alopecia market estimates and forecast, 2018 - 2030
• Fig. 30 Traction alopecia market estimates and forecast, 2018 - 2030
• Fig. 31 Male traction market estimates and forecast, 2018 - 2030
• Fig. 32 Female traction market estimates and forecast, 2018 - 2030
• Fig. 33 Alopecia totalis market estimates and forecast, 2018 - 2030
• Fig. 34 Male alopecia totalis market estimates and forecast, 2018 - 2030
• Fig. 35 Female alopecia totalis market estimates and forecast, 2018 - 2030
• Fig. 36 Alopecia universalis market estimates and forecast, 2018 - 2030
• Fig. 37 Male alopecia universalis market estimates and forecast, 2018 - 2030
• Fig. 38 Female alopecia universalis market estimates and forecast, 2018 - 2030
• Fig. 39 Androgenetic alopecia market estimates and forecast, 2018 - 2030
• Fig. 40 Male androgenetic alopecia market estimates and forecast, 2018 - 2030
• Fig. 41 Female androgenetic alopecia market estimates and forecast, 2018 - 2030
• Fig. 42 Other alopecia market estimates and forecast, 2018 - 2030
• Fig. 43 Male other alopecia market estimates and forecast, 2018 - 2030
• Fig. 44 Female other alopecia market estimates and forecast, 2018 - 2030
• Fig. 45 Alopecia Market: Treatment movement Analysis
• Fig. 46 Alopecia market: Treatment outlook and key takeaways
• Fig. 47 Pharmaceuticals market estimates and forecasts, 2018 - 2030
• Fig. 48 Topical market estimates and forecasts, 2018 - 2030
• Fig. 49 Topical OTC pharmaceuticals market estimates and forecasts, 2018 - 2030
• Fig. 50 Topical OTC minoxidil market estimates and forecasts, 2018 - 2030
• Fig. 51 Topical OTC others market estimates and forecasts, 2018 - 2030
• Fig. 52 Topical prescription pharmaceuticals market estimates and forecasts, 2018 - 2030
• Fig. 53 Topical prescription betamethasone dipropionate market estimates and forecasts, 2018 - 2030
• Fig. 54 Topical prescription fluocinolone acetonide market estimates and forecasts, 2018 - 2030
• Fig. 55 Topical prescription finasteride market estimates and forecasts, 2018 - 2030
• Fig. 56 Topical prescription minoxidil market estimates and forecasts, 2018 - 2030
• Fig. 57 Oral pharmaceuticals market estimates and forecasts, 2018 - 2030
• Fig. 58 Oral OTC pharmaceuticals market estimates and forecasts, 2018 - 2030
• Fig. 59 Oral prescription pharmaceuticals market estimates and forecasts, 2018 - 2030
• Fig. 60 Oral prescription minoxidil market estimates and forecasts, 2018 - 2030
• Fig. 61 Oral prescription finasteride market estimates and forecasts, 2018 - 2030
• Fig. 62 Oral prescription corticosteroids market estimates and forecasts, 2018 - 2030
• Fig. 63 Oral prescription others (JAK inhibitors and others) market estimates and forecasts, 2018 - 2030
• Fig. 64 PRP market estimates and forecasts, 2018 - 2030
• Fig. 65 Devices market estimates and forecasts, 2018 - 2030
• Fig. 66 Laser cap market estimates and forecasts, 2018 - 2030
• Fig. 67 Laser comb market estimates and forecasts, 2018 - 2030
• Fig. 68 Laser helmet market estimates and forecasts, 2018 - 2030
• Fig. 69 Alopecia market: Gender movement analysis
• Fig. 70 Alopecia market: Gender outlook and key takeaways
• Fig. 71 Male market estimates and forecasts, 2018 - 2030
• Fig. 72 Female market estimates and forecasts, 2018 - 2030
• Fig. 73 Alopecia market: Sales channel movement analysis
• Fig. 74 Alopecia market: Sales channel outlook and key takeaways
• Fig. 75 Prescriptions market estimates and forecasts, 2018 - 2030
• Fig. 76 OTC market estimates and forecasts, 2018 - 2030
• Fig. 77 Alopecia market: End use movement analysis
• Fig. 78 Alopecia market: End use outlook and key takeaways
• Fig. 79 Homecare settings market estimates and forecasts, 2018 - 2030
• Fig. 80 Dermatology clinics market estimates and forecasts, 2018 - 2030
• Fig. 81 Global alopecia market: Regional movement analysis
• Fig. 82 Global alopecia market: Regional outlook and key takeaways
• Fig. 83 North America
• Fig. 84 North America market estimates and forecasts, 2018 - 2030
• Fig. 85 U.S.
• Fig. 86 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 87 Canada
• Fig. 88 Canada market estimates and forecasts, 2018 - 2030
• Fig. 89 Mexico
• Fig. 90 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 91 Europe
• Fig. 92 Europe market estimates and forecasts, 2018 - 2030
• Fig. 93 UK
• Fig. 94 UK market estimates and forecasts, 2018 - 2030
• Fig. 95 Germany
• Fig. 96 Germany market estimates and forecasts, 2018 - 2030
• Fig. 97 France
• Fig. 98 France market estimates and forecasts, 2018 - 2030
• Fig. 99 Italy
• Fig. 100 Italy market estimates and forecasts, 2018 - 2030
• Fig. 101 Spain
• Fig. 102 Spain market estimates and forecasts, 2018 - 2030
• Fig. 103 Denmark
• Fig. 104 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 105 Sweden
• Fig. 106 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 107 Norway
• Fig. 108 Norway market estimates and forecasts, 2018 - 2030
• Fig. 109 Asia Pacific
• Fig. 110 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 111 China
• Fig. 112 China market estimates and forecasts, 2018 - 2030
• Fig. 113 Japan
• Fig. 114 Japan market estimates and forecasts, 2018 - 2030
• Fig. 115 India
• Fig. 116 India market estimates and forecasts, 2018 - 2030
• Fig. 117 Thailand
• Fig. 118 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 119 South Korea
• Fig. 120 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 121 Australia
• Fig. 122 Australia market estimates and forecasts, 2018 - 2030
• Fig. 123 Latin America
• Fig. 124 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 125 Brazil
• Fig. 126 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 127 Argentina
• Fig. 128 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 129 Middle East and Africa
• Fig. 130 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 131 South Africa
• Fig. 132 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 133 Saudi Arabia
• Fig. 134 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 135 UAE
• Fig. 136 UAE market estimates and forecasts, 2018 - 2030
• Fig. 137 Kuwait
• Fig. 138 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 139 Market share of key market players- Alopecia market

Alopecia Market Growth & Trends:

The global alopecia market size is expected to reach USD 16.02 billion by 2030, registering a CAGR of 8.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of JAK inhibitors and tyrosine kinase inhibitors along with the rising target disease prevalence is expected to drive market growth.

The prevalence of alopecia areata (AA) and alopecia to talis is increasing globally. It is one of the most commonly encountered problems in clinics in the U.S. As per a research article published in March 2023, in the U.S. and UK, AA accounted for 0.6% to 2% of the new cases encountered in dermatology clinics. In hospital-based studies performed worldwide the incidence of AA is estimated to range between 0.57% to 3.8%.

The approval of new targeted pharmaceutical treatments is a key factor driving the alopecia market growth. For instance, in June 2022, the U.S. FDA approved Lilly's Olumiant oral tablets for the treatment of severe alopecia in adult patients and is the first systemic treatment approved. Another key drug that is anticipated to be approved in 2023 is Pfizer's Ritlecitinib. It is a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinases.

Another key factor driving the industry's growth is the increasing awareness regarding alopecia and thereby increasing treatment rates worldwide. The increase in the level of consciousness regarding physical appearance is one of the major reasons for the rising number of people seeking treatment. Additionally, rising investments in R&D and funding are also fueling market growth.

The limited availability of targeted drugs that treat the underlying condition is one key challenge for the market. While new products with targeted mechanisms of action are being approved the high cost of these drugs in comparison to the already approved products is one of the major hindrances in their widespread adoption.

Alopecia Market Report Highlights:

• The alopecia universalis segment is expected to witness the fastest growth from 2025 to 2030, owing to the impending approval of pipeline products, such as Pfizer's Ritlecitinib which is in the pre-registration phase, and Bioniz Therapeutics's BNZ-1 which is in phase 2 clinical trials
• North America dominated the market in 2024, mainly due to the high consumer awareness, technological advancements, high target disease population, and high healthcare spending
• Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be majorly attributed to the rising target disease population and rising treatment rate for the disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Type
  • 1.2.2. Treatment
  • 1.2.3. Gender
  • 1.2.4. Sales Channel
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease Type
  • 2.2.2. Treatment
  • 2.2.3. Gender
  • 2.2.4. Sales Channel
  • 2.2.5. End Use
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing global prevalence of alopecia
    • 3.2.1.2. Increasing global healthcare expenditure
    • 3.2.1.3. Increasing prevalence of chronic diseases
      • 3.2.1.3.1. PCOS
      • 3.2.1.3.2. Cancer
      • 3.2.1.3.3. Rheumatoid Arthritis
    • 3.2.1.4. Technological advancements in alopecia treatment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of reimbursement policies for alopecia treatment
    • 3.2.2.2. Increasing adoption of substitutes
• 3.3. Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Patent Expiry Analysis
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3

Chapter 4. Alopecia Market: Disease Type Estimates & Trend Analysis

• 4.1. Disease Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Alopecia Market by Disease Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Alopecia Areata
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Male
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Female
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Cicatricial Alopecia
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Male
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Female
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Traction Alopecia
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.2. Male
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.3. Female
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Alopecia Totalis
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.2. Male
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.3. Female
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Alopecia Universalis
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.2. Male
      • 4.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.3. Female
      • 4.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Androgenetic Alopecia
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6.2. Male
      • 4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6.3. Female
      • 4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Others
    • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7.2. Male
      • 4.4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7.3. Female
      • 4.4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Alopecia Market: Treatment Estimates & Trend Analysis

• 5.1. Treatment Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Alopecia Market by Treatment Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Pharmaceuticals
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Topical
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.2. OTC
        • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.2.2. Minoxidil
          • 5.4.1.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.2.3. Others
          • 5.4.1.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.3. Prescription
        • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.2. Betamethasone Dipropionate
          • 5.4.1.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.3. Fluocinolone Acetonide
          • 5.4.1.2.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.4. Finasteride
          • 5.4.1.2.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.2.3.5. Minoxidil
          • 5.4.1.2.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Oral
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.2. OTC
        • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.3. Prescription
        • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.2. Minoxidil
          • 5.4.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.3. Finasteride
          • 5.4.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.4. Corticosteroids
          • 5.4.1.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
        • 5.4.1.3.3.5. Others (JAK inhibitors and others)
          • 5.4.1.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.4. PRP
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Devices
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Laser Cap
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.2. Laser Comb
      • 5.4.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.4. Laser Helmet
      • 5.4.2.2.5. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Alopecia Market: Gender Estimates & Trend Analysis

• 6.1. Gender Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Alopecia Market by Gender Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Male
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Female
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Alopecia Market: Sales Channel Estimates & Trend Analysis

• 7.1. Sales Channel Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Alopecia Market by Gender Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Prescription
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. OTC
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Alopecia Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Alopecia Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Homecare Settings
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Dermatology Clinics
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Alopecia Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. U.S.
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Canada
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. UK
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Germany
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. France
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Italy
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ reimbursement structure
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Spain
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ reimbursement structure
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Norway
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/ reimbursement structure
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Sweden
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ reimbursement structure
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Denmark
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/ reimbursement structure
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Japan
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. China
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. India
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Australia
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. South Korea
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ reimbursement structure
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. Thailand
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ reimbursement structure
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Brazil
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework/ reimbursement structure
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Argentina
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/ reimbursement structure
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. South Africa
    • 9.9.1.1. Key country dynamics
    • 9.9.1.2. Regulatory framework/ reimbursement structure
    • 9.9.1.3. Competitive scenario
    • 9.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.2. Saudi Arabia
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ reimbursement structure
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. UAE
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ reimbursement structure
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. Kuwait
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ reimbursement structure
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key company market share analysis, 2024
  • 10.3.2. Janssen Global Services Inc.
    • 10.3.2.1. Company overview
    • 10.3.2.2. Financial performance
    • 10.3.2.3. Product benchmarking
    • 10.3.2.4. Strategic initiatives
  • 10.3.3. Cipla
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Product benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. Merck & Co., Inc.
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. GSK plc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Sun Pharmaceuticals Industries Ltd
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Dr. Reddy's Laboratories Ltd
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Aurobindo Pharma
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Viatris Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Pfizer, Inc.
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Eli Lilly and Company
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Lexington Intl., LLC (Devices)
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Freedom Laser Therapy (iRestore ID-520 helmet)
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Curallux, LLC.
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. Apira Science Inc. (iGROW Laser)
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Revian Inc.
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Product benchmarking
    • 10.3.16.4. Strategic initiatives
  • 10.3.17. Theradome
    • 10.3.17.1. Company overview
    • 10.3.17.2. Financial performance
    • 10.3.17.3. Product benchmarking
    • 10.3.17.4. Strategic initiatives
  • 10.3.18. Lutronic
    • 10.3.18.1. Company overview
    • 10.3.18.2. Financial performance
    • 10.3.18.3. Product benchmarking
    • 10.3.18.4. Strategic initiatives